Hanall Biopharma Rises 1.58% Amid Immune Oncology Theme Uptrend
On the 3rd, the immuno-oncology theme rose by 3.12% compared to the previous day, showing strong performance, while HanAll BioPharma, a related stock drawing attention, surged by 1.58% compared to the previous day. HanAll BioPharma is known as an R&D-focused pharmaceutical and bio company.
[Graph] Major Stocks' Price Changes in the Immuno-Oncology Theme
According to the analysis by Thinkpool Robo Algorithm RASSI, HanAll BioPharma exceeded the theme's average scores in growth, stability, and profitability, ranking 2nd in the quant financial ranking (out of 26 stocks). This can be interpreted as HanAll BioPharma having relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.
[Table] Top Stocks by Financial Scores within the Theme
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 40s Who Kept Girlfriend's Body for a Year After Murder Sentenced to 30 Years in Prison Again on Appeal
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
※ The quant financial scores are results analyzed by the robo algorithm based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.
※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
